Literature DB >> 29657034

Cost comparison across heart failure patients with reduced and preserved ejection fractions: Analyses of inpatient decompensated heart failure admissions.

Natalia Olchanski1, Amanda R Vest2, Joshua T Cohen3, Peter J Neumann3, David DeNofrio2.   

Abstract

BACKGROUND: Heart failure (HF) is the leading cause of inpatient admissions in the US for adults aged over 65 years and accounts for more than $17 billion in Medicare expenditures annually. There are limited published data on factors influencing expenditure and the relationship between cost and hospital length of stay. We sought to describe institutional costs of HF hospitalization, as well as demographic and clinical predictors of higher hospitalization costs in an academic hospital setting. METHODS AND
RESULTS: Demographic and clinical information was collected retrospectively for 564 unique consecutive patients with a decompensated HF admission during 2010-2013. Forty-six percent had a baseline LVEF >40%, categorized as HF with preserved ejection fraction (HFpEF). Forty-three percent were female and the mean age was 71 years. Patients with reduced ejection fraction (HFrEF) were predominantly male, younger and had a lower burden of baseline comorbidities than HFpEF patients. Length of stay was longer for HFrEF (median 4 days) than HFpEF (median 3 days, p = 0.01). Mean total hospitalization cost was $9521. Mean costs trended higher for HFrEF patients than for HFpEF patients ($10,286 versus $8858, p = 0.07). Room and board contributed more than half of all costs.
CONCLUSIONS: In this single-center study, we observed a trend towards higher HF hospitalization costs for patients with HFrEF, compared to HFpEF, even though patients with HFpEF are older and had more comorbid conditions. Costs were largely driven by length of stay, with higher heart rate at admission, lower systolic blood pressure, and higher creatinine associated with higher inpatient costs.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Healthcare costs; Healthcare economics; Heart failure; Hospitalizations

Mesh:

Year:  2018        PMID: 29657034     DOI: 10.1016/j.ijcard.2018.03.024

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  6 in total

1.  Comparing inpatient costs of heart failure admissions for patients with reduced and preserved ejection fraction with or without type 2 diabetes.

Authors:  Natalia Olchanski; Amanda R Vest; Joshua T Cohen; David DeNofrio
Journal:  Cardiovasc Endocrinol Metab       Date:  2020-02-21

Review 2.  Hospitalisation costs associated with heart failure with preserved ejection fraction (HFpEF): a systematic review.

Authors:  Hannah Clark; Rezwanul Rana; Jeff Gow; Melissa Pearson; Tom van der Touw; Neil Smart
Journal:  Heart Fail Rev       Date:  2021-03-25       Impact factor: 4.214

3.  Relationship Between Heart Failure Hospitalization Costs and Left Ventricular Ejection Fraction in an Advanced Aging Society.

Authors:  Ryota Kaichi; Kyohei Marume; Michikazu Nakai; Masanobu Ishii; Soshiro Ogata; Yoshitaka Iwanaga; Sou Ikebe; Takayuki Mori; Soichi Komaki; Hiroaki Kusaka; Reiko Toida; Kazumasa Kurogi; Yoshihiro Miyamoto; Nobuyasu Yamamoto
Journal:  Circ Rep       Date:  2021-11-17

4.  Healthcare resource utilization and costs among patients with heart failure with preserved, mildly reduced, and reduced ejection fraction in Spain.

Authors:  Carlos Escobar; Beatriz Palacios; Luis Varela; Martín Gutiérrez; Mai Duong; Hungta Chen; Nahila Justo; Javier Cid-Ruzafa; Ignacio Hernández; Phillip R Hunt; Juan F Delgado
Journal:  BMC Health Serv Res       Date:  2022-10-08       Impact factor: 2.908

5.  Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.

Authors:  Javed Butler; Laurence M Djatche; Baanie Sawhney; Sreya Chakladar; Lingfeng Yang; Joanne E Brady; Mei Yang
Journal:  Adv Ther       Date:  2020-08-06       Impact factor: 3.845

Review 6.  A Systematic Review of Medical Costs Associated with Heart Failure in the USA (2014-2020).

Authors:  Michael Urbich; Gary Globe; Krystallia Pantiri; Marieke Heisen; Craig Bennison; Heidi S Wirtz; Gian Luca Di Tanna
Journal:  Pharmacoeconomics       Date:  2020-11       Impact factor: 4.981

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.